-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35

Benzinga·09/11/2025 14:30:18
Listen to the news
Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.